InvestorsObserver
×
News Home

Should You Add Lexicon Pharmaceuticals Inc (LXRX) Stock to Your Portfolio Wednesday?

Wednesday, March 13, 2024 12:44 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Lexicon Pharmaceuticals Inc (LXRX) Stock to Your Portfolio Wednesday?

Lexicon Pharmaceuticals Inc (LXRX) is near the top in its sector according to InvestorsObserver. LXRX gets an overall rating of 34. That means it scores higher than 34% of stocks. Lexicon Pharmaceuticals Inc gets a 90 rank in the Healthcare sector. Healthcare is number 2 out of 11 sectors.

Overall Score - 34
LXRX has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on LXRX!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 34 means the stock is more attractive than 34 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Lexicon Pharmaceuticals Inc Stock Today?

Lexicon Pharmaceuticals Inc (LXRX) stock is trading at $2.50 as of 12:40 PM on Wednesday, Mar 13, a decline of -$0.03, or -0.99% from the previous closing price of $2.52. The stock has traded between $2.43 and $2.64 so far today. Volume today is low. So far 3,240,645 shares have traded compared to average volume of 6,065,334 shares. Click Here to get the full Stock Report for Lexicon Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App